Periactin

Critical Warnings & Restrictions In Canada (Safety First)

Basic Periactin Information

• INN (International Nonproprietary Name): Cyproheptadine.
• Brand Names Available In Canada (English): Periactin, Ciplactin, Ciproheptadina, Cyproheptadine, Cyheptine, Cyllermin, Apeplus, Apitup, Biohept, Periactine, Reactin, Periatin, Ciptadine — note that these brand names and packaging are listed in international registries and may not all be marketed in Canada; clinicians should verify local market availability and DINs.
• ATC Code: R06AX02.
• Forms & Dosages: Tablets 4 mg (common), Syrup 2 mg/5 ml (common in some markets).
• Manufacturers In Canada (English): Not specified in the supplied data; international manufacturers include Viatris (Australia), Auden Mckenzie and Cipla (India), Teva and Boscogen (USA), Teofarma and Arena (Europe).
• Registration Status In Canada (English): Not specified in the supplied data; international registrations include AUST R 62384 (Australia) and FDA listings (USA); always check Health Canada Drug Product Database for current status and active DIN(s).
• OTC / Rx Classification: Internationally variable — OTC in Australia and India for some presentations, prescription-only (Rx) in USA and EU; Canadian status is not specified in the supplied data and must be confirmed via Health Canada and provincial formularies.

High-Risk Groups

Who Should Be Flagged Before Periactin Is Considered?

• Elderly — higher risk of delirium, falls and sedation.
• Pregnant or breastfeeding people — assess risk versus benefit before use.
• Children under 2 years — do not use.
• People with hepatic or renal impairment — use cautiously and consider lower starting doses.
• History of seizures — use with caution.
• Significant prostatic hypertrophy — risk of urinary retention.
• Indigenous patients — provide culturally safe counselling and involve primary care or Indigenous health services as needed.
• Absolute contraindications to screen for: allergy to cyproheptadine or excipients, newborns/premature infants, angle-closure glaucoma, bladder neck obstruction, recent or concurrent use of MAOIs (within 14 days).

Pre-Prescription Screening Checklist

• Allergies: Record any known allergy to cyproheptadine or formulation excipients.
• Current Medications: List all prescription, OTC and herbal products (pay special attention to MAOIs, sedatives, tricyclics).
• Pregnancy Status: Confirm pregnancy or breastfeeding status and document discussion of risks.
• Age: Verify patient is ≥2 years for use; note increased risk in elderly.
• Comorbidities: Check for glaucoma, prostatic hypertrophy, liver or kidney disease, seizure history.

Patient Record Box

• Allergies: ____________________________________
• Current Medications: __________________________
• Pregnancy/Breastfeeding Status: ________________
• Special Notes (Indigenous Health Liaison Involved?): ______________

Interaction With Activities (Driving, Machinery, Workplace Safety Under Canadian Law)

Will This Medicine Affect Driving Or Safety-Sensitive Work?

Cyproheptadine commonly causes drowsiness, dizziness and impaired concentration.

Patients must be advised that reaction time and alertness can be reduced while taking this antihistamine.

Under Canadian impaired-driving law, operating a vehicle while impaired by a prescription medication can have legal consequences.

Employers may have workplace safety policies that restrict use of sedating drugs in safety-sensitive roles.

Patient Counselling Checklist

• Do not drive or operate heavy machinery until you know how cyproheptadine affects you.
• If you feel drowsy, dizzy or slowed in reaction time after taking the medicine, do not drive.
• Avoid alcohol and other central nervous system depressants while adjusting to the medicine.
• Discuss workplace restrictions with your employer or occupational health if you work in a safety-sensitive position.

Q&A — Can I Drive After Taking Periactin/Cyproheptadine In Canada?

No.

Advise patients not to drive or operate heavy machinery until they know whether cyproheptadine causes drowsiness or slowed reaction time.

If sedation occurs, the patient should not drive.

This advice aligns with Canadian impaired-driving safety expectations and common workplace safety policies.

Usage Basics For Canadians

INN, Brand Names Available In Canada

What Names Might Patients Recognize?

The International Nonproprietary Name is cyproheptadine.

Periactin is the globally recognized brand, and cyproheptadine is also marketed under many other names internationally including Ciplactin, Ciproheptadina and generic cyproheptadine.

Table: Brand Mappings

Definition List

• INN: International Nonproprietary Name, which is cyproheptadine.
• DIN: Drug Identification Number — check the Health Canada Drug Product Database for current DIN(s) before prescribing or dispensing.
• ATC: Anatomical Therapeutic Chemical classification — R06AX02 for cyproheptadine.

Legal Classification Under Health Canada (Prescription Vs OTC)

Is Periactin Available Over The Counter In Canada?

Legal classification varies by country.

Periactin and cyproheptadine are OTC in some countries such as Australia and India for certain presentations and Rx in the USA and EU.

Canadian status is not specified in the supplied data and must be confirmed via Health Canada and provincial formularies.

Action Checklist For Clinicians And Pharmacists

• Check the Health Canada Drug Product Database for current marketed products and active DIN(s).
• Verify provincial rules and formularies before prescribing or dispensing.
• Confirm whether any particular presentation is sold OTC or requires a prescription in the patient’s province.

Canadian Dosing Guide

Standard Regimens

What Doses Are Used Commonly?

Typical dosing from available international data is:

• Adults: 4 mg (one 4 mg tablet) up to three times daily for allergic reactions.
• Pediatrics (≥2 years): 2 mg (half a 4 mg tablet) two to three times daily.
• Appetite stimulation: 2–4 mg up to three times daily, individualized per patient response.
• Migraine prophylaxis (off-label): 4 mg up to three times daily, under specialist guidance.

Pediatric Weight-Based Table

Monitoring Checklist

• Monitor sedation and dizziness, especially during initiation and dose changes.
• Watch for urinary retention and visual disturbance in at‑risk patients.
• For appetite stimulation, assess weight and nutritional intake after 2–6 weeks.

Adjustments For Comorbidities

How To Adjust For Liver, Kidney, Diabetes And Other Conditions?

• Start at a lower initial dose in hepatic or renal impairment and monitor closely.
• In elderly patients, use the lower end of dosing ranges because of increased CNS sensitivity.
• In people with diabetes, monitor glycaemic control if appetite increases or weight gain occurs.

Q&A — Missed Dose And Provincial Drug Plans

If A Dose Is Missed: Take as soon as remembered unless it is close to the next scheduled dose.

Do not double the next dose to make up for a missed dose.

Provincial drug coverage does not change how to take missed doses.

Contact your pharmacist for procedures on replacement supplies or emergency refill options under your provincial plan.

Interaction Chart (Canadian Context)

Food And Drinks

What About Alcohol, Coffee Or Other Common Substances?

Alcohol and other central nervous system depressants can increase sedation when combined with cyproheptadine.

Caffeine or coffee will not reliably reverse the sedative effects of cyproheptadine and should not be relied upon for safety-sensitive tasks.

Common Drug Conflicts

Which Medications Cause Concern?

• Monoamine Oxidase Inhibitors (MAOIs) — contraindicated within 14 days of MAOI use.
• Medications with anticholinergic activity such as tricyclic antidepressants and some antipsychotics — additive anticholinergic burden may increase confusion, urinary retention and dry mouth.
• Other first-generation antihistamines or sedatives — increased sedation risk.
• Review the full medication list before starting cyproheptadine and use electronic interaction checks where available.

Immediate Actions For Interactions

• Pause or avoid MAOI therapy within 14 days of cyproheptadine.
• Consult pharmacist or prescriber before adding cyproheptadine to a regimen with other sedatives.
• Use pharmacy e‑interaction tools or provincial electronic health records to check for interactions.

User Reports & Trends In Canada

Canadian Patient Forums And Review Platforms

What Do Patients Commonly Search For And Report?

Patients often search for Periactin as an appetite stimulant and as treatment for allergies.

Common anecdotal effects reported include increased appetite, weight gain and drowsiness.

Some parents report paradoxical excitation in children after first-generation antihistamines.

Community Pharmacy Feedback

What Pharmacists See At The Counter

• Frequent questions about off‑label appetite use and safety in the elderly.
• Requests for advice on sedation and suitability with other medicines.
• Documentation of adverse events helps build local real-world safety data.

Checklist For Capturing User Reports

• Date of report.
• Product name and DIN if available.
• Dose taken and duration.
• Reported effects and any action taken.

Where To Report Suspected Adverse Events In Canada

Report suspected adverse reactions to the appropriate national reporting body such as Canada Vigilance via their online reporting form or telephone service.

Access & Purchase Options

National Pharmacy Chains And In-Store Reality

Where Can Patients Expect To Find Periactin In Canada?

Major chains including Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu can dispense prescription antihistamines subject to availability and provincial rules.

These pharmacies typically offer pharmacist consultation and private counselling services.

Online Pharmacies In Canada & Provincial Restrictions

How To Buy Safely Online

• Ensure the online pharmacy is licensed and operates in Canada.
• Verify the product DIN on the product page where provided.
• Do not import from unknown international sellers because formulations and concentrations can vary.

Safe Purchase Checklist

• Confirm prescription requirement for your province.
• Verify the pharmacy licence and Canadian contact details.
• Check for clear DIN and bilingual labelling where applicable, especially for Quebec customers.
• Review return and privacy policies.

Note About This Pharmacy

In our online pharmacy, periactin is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Mechanism & Pharmacology

Simplified Explanation (Patient-Friendly)

What Does Periactin Do?

Cyproheptadine is a first-generation antihistamine with ATC code R06AX02.

It blocks H1 histamine receptors which reduces allergy symptoms such as itching and rhinorrhea.

It also has antiserotonergic and anticholinergic effects that can increase appetite and cause common side effects like drowsiness and dry mouth.

Definitions

• Antihistamine: A drug that blocks histamine receptors to relieve allergy symptoms.
• Antiserotonergic: A drug action that blocks some serotonin receptors, which may influence appetite.
• Anticholinergic: An action that blocks acetylcholine receptors, often causing dry mouth, blurred vision and urinary retention.

Clinical Terms

Onset and Duration

Onset of action is typically within 30–60 minutes and effects can last several hours.

Compared with second-generation antihistamines such as loratadine, cetirizine and fexofenadine, cyproheptadine has a higher sedative profile.

Indications & Off-Label Uses In Canada

Approved Indications (DIN)

What Is Periactin Used For?

Internationally, cyproheptadine is indicated for allergic reactions, itching and rhinitis.

Appetite stimulation is a commonly reported off‑label use in some settings.

Canadian-specific approved indications and DIN(s) are not specified in the supplied data and must be confirmed via Health Canada.

Common Off-Label Practices

Where Is Periactin Used Off-Label?

• Appetite stimulant for paediatric failure to thrive or adult cachexia — evidence is limited and use requires close supervision.
• Migraine prophylaxis in some specialist practices — requires specialist oversight.

Prescriber Checklist For Off-Label Use

• Document rationale for off‑label use in the chart.
• Record baseline weight and relevant labs where applicable.
• Plan a monitoring schedule for efficacy and adverse effects.
• Obtain and document informed consent discussing benefits and risks.

Key Clinical Findings

Canadian And International Studies (2022–2024) And Evidence Summary

What Does The Evidence Say?

International literature indicates cyproheptadine can increase appetite and weight in some patients, though high‑quality randomized controlled trial evidence for many off‑label uses is limited.

Sedation and anticholinergic adverse events are commonly reported across studies and case reports.

• Efficacy signals exist for appetite stimulation in small studies and case series.
• Common adverse events include drowsiness, dry mouth and dizziness.
• Use in elderly or in combination with anticholinergic drugs increases risk of confusion and falls.

Ongoing Health Canada Safety Monitoring

How Should Clinicians Monitor Safety?

Clinicians should consult Health Canada updates and provincial advisories for post‑market safety information.

Alternatives Matrix

Comparable Medicines With DIN In Canada

What Alternatives Should Be Considered?

Pros And Cons Checklist

• Pros Of Cyproheptadine: potential appetite stimulation, effective H1 antagonism for allergic symptoms.
• Cons Of Cyproheptadine: sedation, anticholinergic burden, contraindications such as MAOI use and angle-closure glaucoma, limited clear availability data for Canada in the supplied dataset.
• Decision Aids: match the drug to the indication, consider patient occupation, age and comorbidities, choose a lower‑sedation alternative when safety is a priority.

Common Questions From Canadian Patients

Top Questions With Short Answers For Pharmacy Handouts

• Is Periactin Safe For My Child? — Not for children under 2 years; watch for paradoxical excitation in some children and follow pediatric dosing guidance.
• Will It Help Me Gain Weight? — It may increase appetite and weight in some patients, but use requires supervision and monitoring.
• Can I Take It With My Antidepressant? — Check for MAOIs and anticholinergic interactions; consult your pharmacist or prescriber before combining.
• How Do I Report Side Effects? — Report suspected adverse events through national reporting channels such as Canada Vigilance.
• What If I Am Pregnant Or Breastfeeding? — Assess risk versus benefit with your prescriber; data are limited and close monitoring is required.
• What Are The Main Side Effects? — Drowsiness, dry mouth, dizziness and increased appetite are common.
• Can I Take It With Alcohol? — Avoid alcohol while adjusting to the medicine due to increased sedation risk.
• Where Can I Buy It? — Check with licensed Canadian pharmacies and verify DIN and provincial rules.

Referral Templates

• Refer To Local Pharmacist: Contact your community pharmacist for a medication review and counselling on interactions.
• Refer To Family Physician: Arrange a follow-up for off‑label appetite use or if adverse effects occur.

Coverage & Purchase Comparison Table

Province And Plan Coverage Considerations

How Do Provincial Plans Typically Handle This Medicine?

Coverage for cyproheptadine varies by indication and province, and many off‑label uses are unlikely to be covered without special authorization.

Step-By-Step Purchase Checklist For Canadian Patients

1. Verify whether a prescription is required in your province and check the product DIN.
2. Check provincial formularies for coverage or special authorization requirements.
3. Choose a licensed pharmacy in Canada, in-store or accredited online.
4. Ask the pharmacist for counselling on sedation, interactions and safe use.
5. Understand likely cost and ask about generic options to reduce expense.

Registration & Regulation

Health Canada Approval

How To Verify Approval Status

Search the Health Canada Drug Product Database to confirm current approval status and active DIN(s) for cyproheptadine products.

The supplied data shows international registrations but does not specify a Canada DIN, so do not assume market status without verification.

Regulatory Verification Checklist

• Search Health Canada Drug Product Database for product name and DIN.
• Confirm the product monograph and approved indications if a Canadian DIN exists.
• Check provincial formulary listings and any special authorization processes.

DIN Number And Labelling Requirements

What Documentation Should Be Kept?

• Ensure prescriptions, dispensing records and counselling notes are filed per provincial standards.
• Provide bilingual materials where required by provincial rules, especially in Quebec.
• Document informed consent when using cyproheptadine off‑label for appetite stimulation or other non‑label uses.

Storage & Handling

Standard Canadian Household Conditions

How Should Patients Store Periactin At Home?

Store below 25°C (77°F) and protect from moisture and light.

Keep tablets or syrup in their original packaging and out of reach of children and pets.

No routine refrigeration is required for standard tablet or syrup formulations.

Patient Handout Checklist

• Store at room temperature below 25°C (77°F).
• Protect from moisture and light.
• Discard after expiry and keep out of reach of children.

Cold-Chain Requirements

Is Refrigeration Needed?

No cold-chain is required for tablets or syrup formulations in normal retail distribution.

Pharmacies should maintain stock at recommended room temperature and rotate stock by expiry date.

Guidelines For Proper Use

Canadian Pharmacist Guidance

Pharmacist Counselling Checklist

• Confirm the indication and diagnosis before dispensing cyproheptadine.
• Review the full medication list for MAOIs, sedatives and anticholinergic agents.
• Assess contraindications including glaucoma, urinary retention and pregnancy.
• Advise on driving and workplace safety related to sedation.
• Provide written patient information and counsel on how to report adverse events.
• Document counselling in the patient record including any off‑label consent.

Provincial Health Authority Recommendations

Shared Decision-Making And When To Stop Therapy

• Follow provincial formularies and clinical guidance when authorizing off‑label use.
• Use shared decision‑making and document informed consent for appetite stimulation or other non‑label indications.
• Stop therapy and seek medical attention for severe sedation, urinary retention, sudden visual changes or signs of allergic reaction.
• Emergency instructions for overdose: look for CNS depression or excitation and anticholinergic signs such as dry mouth and dilated pupils and seek emergency care.

Delivery Across Canada (English)